Guo Qianyu, Li Jie, Wang Juanjuan, Li Linxin, Wei Jia, Zhang Liyun
Department of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Front Pharmacol. 2024 Dec 12;15:1502298. doi: 10.3389/fphar.2024.1502298. eCollection 2024.
CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others. However, CAR-T therapy faces difficulties such as time-consuming cell manufacturing, complex and expensive process, and the possibility of severe adverse reactions complicating the treatment, etc. This article examines CAR-T therapy across various rheumatic autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic sclerosis (SSc), antisynthetase syndrome (ASS), and ANCA-associated vasculitis (AAV), highlighting both therapeutic advancements and ongoing challenges.
嵌合抗原受体T细胞（CAR-T）疗法是一种前沿的细胞免疫疗法，已证明在治疗血液系统恶性肿瘤方面有效，在治疗自身免疫性疾病方面也显示出巨大潜力。这种创新的治疗方法有望实现自身免疫性疾病的长期缓解，可能为受影响的患者带来显著益处。目前正在研究用于治疗这些疾病的靶点包括CD19、CD20和B细胞成熟抗原（BCMA）等。然而，CAR-T疗法面临一些困难，如细胞制造耗时、过程复杂且昂贵，以及可能出现严重不良反应使治疗复杂化等。本文探讨了CAR-T疗法在各种风湿性自身免疫性疾病中的应用，包括系统性红斑狼疮（SLE）、类风湿关节炎（RA）、干燥综合征（SS）、系统性硬化症（SSc）、抗合成酶综合征（ASS）和抗中性粒细胞胞浆抗体相关性血管炎（AAV），重点介绍了治疗进展和持续存在的挑战。
